What GLP Chart is
GLP Chart is an independent GLP-1 price tracker. We follow 31 US programsacross telehealth, compounded, manufacturer-direct and retail, check every price against the program's published pricing every Monday, and score them on a published 50-point framework. No program pays to be listed and no program can pay to change its rank. Some visit links earn us a commission.
Quotable stats, ready to paste
Every figure here is checked against the program's published pricing and the manufacturer list price. Free to quote with attribution. Want the underlying source link for any one of them? Email press@glpchart.com and we will send it.
| Stat | What it measures | Source |
|---|---|---|
| 31 | US GLP-1 telehealth, compounded, manufacturer-direct and retail programs tracked, prices checked every Monday. | GLP Chart, June 2026 |
| $178/mo | Compounded semaglutide at a flat month-to-month rate, all-in cash-pay (Mochi Health, same price at every dose). | GLP Chart Price Index, June 2026 |
| $1,349/mo | Branded Wegovy at the retail cash price, before insurance. | Novo Nordisk list price, via GLP Chart |
| $998/mo | Branded Ozempic at the retail cash price, before insurance. | Novo Nordisk list price, via GLP Chart |
| $1,099/mo | Branded Zepbound at the retail cash price, before insurance. | Eli Lilly list price, via GLP Chart |
| $299/mo | Cheapest branded direct: Wegovy maintenance via NovoCare, Zepbound vials via LillyDirect. | GLP Chart, June 2026 |
| 7.6x | Price spread for the same molecule: branded Wegovy ($1,349) versus compounded semaglutide ($178). | GLP Chart, June 2026 |
Prices are cash-pay before insurance unless noted. Branded retail figures are the manufacturer list price. Compounded figures are 503A pharmacy cash-pay through the telehealth programs we track.
Free data
Free to use, free to cite, attribution appreciated. Everything below is published under CC BY 4.0.
- Price Index CSV (June 2026) every program, every drug, maintenance price, lock-in, score and the five sub-scores.
- Price-history CSV and JSON dated month-over-month snapshots, so you can chart a program's price moves over time.
- GLP-1 Price Report 2026 the editorial report behind the numbers: the cash-pay spread, teaser-versus-maintenance gaps, compounded versus branded, and every price move so far this year.
- Price Index PDF (June 2026 edition) the chart and methodology in one file, ready to send to a source.
- facts.json the machine-readable canonical fact sheet, for AI search and automated citation.
The live numbers, as of July 13
These fall straight out of the data and update every Monday, so a quote stays current. They use the all-in cash-pay basis: the monthly figure includes the maintenance-dose medication.
- 31 US GLP-1 telehealth programs tracked on the chart.
- $149/mo the cheapest all-in cash-pay total, drug included (Strut Health).
- $299/mo the median all-in cash-pay total across all programs.
- $448/mo the most expensive all-in cash-pay total (LifeMD).
- 3.0x the price ratio between cheapest and most expensive on the same basis.
All-in means the monthly figure includes the maintenance-dose medication. Membership-only fees (drug billed separately) and insurance-dependent copays (a with-coverage price, not a cash total) are not counted as the cheapest cash-pay all-in, the same basis the Price Index uses.
See the full June 2026 Price Index for the per-program breakdown, or pull the change-log JSON feed directly.
What moved this week
Every Monday we check all 31 programs against their published pricing. This is what changed: who raised or cut a price, who added or dropped a lock-in, who restructured, who exited the US. Each entry is dated to the week it was verified.
Spotted something? If you catch a program quietly raising a price or slipping in a new lock-in before we do, tell us at tips@glpchart.com. We verify and date every report.
Price Index, June 2026
Download the source data or embed the live widget.
- CSV every program, every drug, maintenance price, lock-in, score and five sub-scores.
- PDF report (June 2026 edition) editorial summary with methodology and the full chart, ready to send to a source.
- Full landing page the live, sortable chart with every program and sub-score.
Embed the widget. One iframe, no JavaScript, no tracking cookies. It pulls the latest top-five programs by cash-pay maintenance price and refreshes every Monday.
<iframe src="https://glpchart.com/price-index/embed/" width="100%" height="380" frameborder="0" loading="lazy" title="GLP Chart Price Index, June 2026" style="border: 1px solid #eaeaea; border-radius: 2px; max-width: 720px;"></iframe>Renders in WordPress, Webflow, Ghost, Substack and any CMS that allows raw HTML. For paste-ready quote cards and the journalist FAQ, see the Price Index page.
How we verify
Every price is verified against the program's published pricing page, checked every Monday. We read the program's own pricing page for the maintenance-dose figure, and when a program's site blocks automated access we confirm the published number through a web search of the program's own materials. When a program runs a separate cash-pay rail and an insurance-routed rail, we report the cash-pay number. For any number you want to cite, we will send the published source: a link to the program's pricing page or the manufacturer pricing page it came from. Email press@glpchart.com with the specific stat.
For the scoring framework and the five sub-score definitions, see the methodology page. For how we stay independent of the programs we rank, see why trust us.
A nameable expert, on the record
Topics he can speak to:
- The economics of compounded GLP-1. Why the supply moved off the shortage list, how 503A pharmacies adapted, what the “personalized formulation” trend means in 2026.
- Insurance prior-authorization mechanics. The documented criteria, the appeal pathways, the denial rate by carrier where available.
- Wegovy vs Zepbound. Trial-versus-real-world adherence, dose-response curves, the dropout problem in both registration trials.
- Maintenance dosing and discontinuation. What happens when patients stop, the regain curve, what industry is and is not saying about lifetime use.
- Telehealth program differentiation. Which models work, which are racing to the bottom on price, which are quietly upselling into supplements and coaching.
Request data or a quote
Tell us the stat, table row or claim you want sourced and we will send the underlying file. We reply within one business day, US Central time.
John Samaras, founder and editor: press@glpchart.com · +1 (646) 305-3003 (WhatsApp) · press desk press@glpchart.com or WhatsApp +1 (646) 305-3003.
Citation terms
The GLP Chart Price Index and change-log are published under Creative Commons CC BY 4.0. Reuse any number, table row, chart or quote card with attribution and a link back. Suggested citation:
GLP Chart Price Index, June 2026. glpchart.com/price-index. Verified July 13, 2026.
For source-level documentation (links to the published program and manufacturer pricing pages each figure came from), email press@glpchart.com or message us on WhatsApp +1 (646) 305-3003. For embargoed pre-release of next quarter's figures, reach us at least 72 hours before publication.